Acuta Capital Partners LLC Acquires 35,400 Shares of Insmed Incorporated (NASDAQ:INSM)

Acuta Capital Partners LLC raised its holdings in Insmed Incorporated (NASDAQ:INSM) by 49.1% during the 3rd quarter, Holdings Channel reports. The firm owned 107,500 shares of the biopharmaceutical company’s stock after purchasing an additional 35,400 shares during the quarter. Insmed comprises 6.4% of Acuta Capital Partners LLC’s investment portfolio, making the stock its 4th biggest holding. Acuta Capital Partners LLC’s holdings in Insmed were worth $7,848,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. V Square Quantitative Management LLC acquired a new position in shares of Insmed during the 3rd quarter worth approximately $30,000. GAMMA Investing LLC increased its position in Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 224 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 287 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares in the last quarter. Finally, CWM LLC boosted its stake in shares of Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 155 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on INSM shares. TD Cowen upped their target price on shares of Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a report on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. boosted their price target on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. Stifel Nicolaus raised their price objective on Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, UBS Group upped their target price on Insmed from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $83.67.

Insider Transactions at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the transaction, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. The trade was a 11.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the sale, the insider now owns 100,100 shares of the company’s stock, valued at $7,157,150. This represents a 27.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 78,882 shares of company stock valued at $5,765,446 over the last quarter. Company insiders own 4.60% of the company’s stock.

Insmed Trading Up 0.3 %

Shares of INSM stock opened at $75.88 on Thursday. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The firm’s 50 day moving average price is $72.16 and its two-hundred day moving average price is $67.34. The stock has a market cap of $13.57 billion, a price-to-earnings ratio of -13.67 and a beta of 1.12.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $93.36 million. During the same period last year, the business posted ($1.10) earnings per share. The company’s revenue for the quarter was up 18.1% compared to the same quarter last year. On average, analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.